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While T cell-based immunotherapies are steadily improving, there are still many patients 
who progress, despite T cell-infiltrated tumors. Emerging evidence suggests that 
T cells themselves may provoke immune escape of cancer cells. Here, we describe a 
well-controlled co-culture system for studying the dynamic T cell – cancer cell interplay, 
using human melanoma as a model. We explain starting material, controls, and culture 
parameters to establish reproducible and comparable cultures with highly heteroge-
neous tumor cells. Low passage melanoma cell lines and melanoma-specific CD8+ 
T cell clones generated from patient blood were cultured together for up to 3 days. Living 
melanoma cells were isolated from the co-culture system by fluorescence-activated cell 
sorting. We demonstrate that the characterization of isolated melanoma cells is feasible 
using flow cytometry for protein expression analysis as well as an Agilent whole human 
genome microarray and the NanoString technology for differential gene expression anal-
ysis. In addition, we identify five genes (ALG12, GUSB, RPLP0, KRBA2, and ADAT2) that 
are stably expressed in melanoma cells independent of the presence of T cells or the T 
cell-derived cytokines IFNγ and TNFα. These genes are essential for correct normaliza-
tion of gene expression data by NanoString. Further to the characterization of melanoma 
cells after exposure to CTLs, this experimental system might be suitable to answer a 
series of questions, including how the affinity of CTLs for their target antigen influences 
the melanoma cell response and whether CTL-induced gene expression changes in 
melanoma cells are reversible. Taken together, our human T cell – melanoma cell culture 
system is well suited to characterize immune-related mechanisms in cancer cells.
Keywords: melanoma, Cd8+ t cell, co-culture, antigen-specific, Nanostring
INtRodUCtIoN
Recently, there have been major breakthroughs in treating cancer patients using T cell-based immu-
notherapy (1, 2), which are promising in cancer types that are immunogenic and patients capable 
to mount an immune response. Prototypes of immunogenic tumors include melanoma, non-small 
cell lung cancer, prostate cancer, and ovarian cancer. Beyond, the list of malignancies responding to 
immunotherapy is rapidly growing (3).
tAbLe 1 | the melanoma cell lines were derived from metastases or tumor-infiltrated lymph nodes of hLA-A2 positive melanoma patients.
Cell line Patient Gender Age at surgery (years) source of cell line hLA-A
Me275 LAU50 Male 65 Lymph node metastasis *02:01, *23:01
Me290 LAU203 Female 65 Lymph node metastasis 1, *02:01
T1015A LAU1015 Male 77 Non-lymphoid metastasis *02:09, 32(19)
T1185B LAU1185 Female 60 Non-lymphoid metastasis *02:01
For the HLA-typing, numbers preceded by an asterisk were determined by molecular biology and the remaining ones by serology. The first one to two digit(s) stand for the “allele 
group”, whereas the four digits stand for the HLA protein.
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The most successful T cell-based therapies for solid cancers 
are adoptive T cell transfer with autologous tumor-infiltrating 
T cells, and inhibitory receptor blockade (checkpoint block-
ade) (3). At the center of these therapies are cytotoxic CD8+ 
T   lymphocytes (CTLs) that can eliminate tumor cells. While 
such therapies prolong patient survival, there is still an important 
fraction of patients where cancers escape from immune attack. 
Experiments in mice have shown that intratumoral CTLs can 
trigger tumor cells to upregulate inhibitory receptor ligands 
(e.g. PDL1) and the immune suppressive enzyme IDO (4, 5), 
suggesting that CTLs themselves might contribute to provoke 
escape from immunotherapy. The large majority of publications 
describe long-term escape variants of tumor cells (6, 7), mouse 
models (4, 8), and data from human bulk tumors (9, 10), which 
are suboptimal for individualized and broad characterization of 
the immediate interplay between specific cell types of the tumor 
microenvironment.
Melanomas develop from melanocytes, pigmented cells mostly 
found in the skin but also in the eye and inner ear. Melanoma 
cells express melanoma-specific antigens, such as the well-char-
acterized melanoma differentiation antigens MelanA (MART-1), 
gp100 (pmel) and tyrosinase (11–13) that can be recognized by 
CTLs via their T cell receptors (TCRs). Many melanoma-specific 
human CTLs and their TCRs have been studied in depth (14–16). 
Thus, human melanomas are well suited for studying CTL–tumor 
cell interactions.
To date, an in vitro system to comprehensively study the imme-
diate interactions of CTLs and tumor cells is missing. We believe 
that short-term co-cultures of melanoma cells with CTLs can be 
useful for studying their dynamic interplay. The challenge of set-
ting up a human in vitro co-culture system consists in the choice 
of appropriate cellular material and experimental parameters that 
lead to reproducible results despite that the cells are from highly 
heterogeneous melanoma patients. Nevertheless, we succeeded in 
establishing suitable methods, and herewith describe the starting 
material, controls, culture parameters, and readouts.
MAteRIALs ANd Methods
Cells and Cell Culture
All cell lines and clones were established at Ludwig Cancer 
Research, Department of Oncology, University of Lausanne. 
Patients consented based on approval of this work obtained 
from the local ethics committee. Melanoma cell lines were 
established from metastatic surgery specimens from melanoma 
patients (Table 1). Melanoma cells were cultured in RPMI 1640 
– GlutaMAXTM-I, complemented with 10% heat-inactivated FCS 
(PAA), 1.1  μM arginine (Sigma Aldrich), 0.48  μM asparagine 
(Sigma Aldrich), 11.25  μM glutamine (Gibco), 10  mM Hepes 
(Gibco), and 100 U/ml of penicillin/streptomycin (Gibco). Where 
indicated, the medium was supplemented with IFNγ (222 U/ml; 
Peprotech), TNFα (50 ng/ml; Peprotech) or both TNFα and IFNγ 
(10 ng/ml and 222 U/ml). CD8+ T cell clones were established 
from antigen-specific CD8+ T cells isolated from PBMCs of mel-
anoma patients or healthy donors and maintained as previously 
described (17, 18) (Table 2). CD8+ T cell clones were cultured 
in RPMI 1640 – GlutaMAXTM-I, supplemented with 100 U/ml of 
penicillin/streptomycin, 2 mM l-glutamine, 1 mM non-essential 
amino acids, 1% Na pyruvate, 0.1 mg/ml Kanamycin (all Gibco), 
5 ×  10−5 2β-mercaptoethanol (Sigma) and 8% human serum. 
Human serum was prepared in house from serum of 30 male 
A+  donors obtained from the CRS Interregional Transfusion 
Center Bern. Serum was subject to tests of proliferation, mixed 
lymphocyte culture, and mycoplasma PCR.
All cell lines and T cells were routinely controlled to be 
mycoplasma-free using PCR. The precise details and setup of the 
co-culture system are described throughout the results section.
Fluorescence-Activated Cell sorting
Before seeding, melanoma cells were labeled with 1 μM CFSE 
(Cell trace CFSE cell proliferation kit, Molecular Probes) and 
CTLs were labeled with 1 μM Violet tracker (Cell trace Violet Cell 
Proliferation kit, Molecular Probes). For intracellular staining, 
cell cultures were treated with BrefeldinA (final concentration: 
10 μg/ml, Sigma Aldrich) for the last 4 h of culture. After harvest-
ing, cells were washed once with PBS, stained with LIVE/DEAD® 
Fixable Aqua Dead Cell Stain Kit (Life Technologies) for 30 min 
and fixed at 4°C overnight in PBS containing 1% Formaldehyde, 
2% Glucose, and 5 mM NaAzide. Then cells were washed once 
with fluorescence-activated cell sorting (FACS) buffer (PBS sup-
plemented with 5  mM EDTA, 0.2% BSA, and 0.2% NaAzide), 
stained with cell surface antibodies for 20 min followed by per-
meabilization and intracellular staining with antibodies in 0.1% 
saponin-containing FACS buffer for 30 min. The following anti-
human antibodies were used: MelanA (clone A103, produced and 
labeled in house), HLA-DR (clone LN3, eBioscience), HLA Class 
I (clone W6/32, Biolegend), CD8 (clone SK1, BD), IFNγ (clone 
B27, BD), and TNFα (clone MAb11, BD). The following matched 
isotype controls were used: mouse IgG1 (produced in house, batch 
24.11.14), mouse IgG2b kappa (clone eBMG2b, eBioscience), 
mouse IgG2a kappa (clone MOPC-173, Biolegend), mouse IgG1 
kappa (clone MPC-11, BD), and IgG1 kappa (clone MOPC-21, 
BD). PE-labeled A2-ELA-specific tetramers (No. 404, TC Metrix) 
were used to stain MelanA-specific CTLs. AnnexinV staining was 
tAbLe 2 | Antigen specificity of CtL clones derived from melanoma 
patients or health donors.
Clone Patient specificity
Clone 1 LAU1185 (melanoma patient) A2/MelanA; EAAGIGILTV (melanoma)
Clone 121 LAU1015 (melanoma patient) A2/MelanA; EAAGIGILTV (melanoma)
Clone N8 LAU5048 (healthy donor) A2/NS4b; LLWNGPMAV  
(Yellow-fever virus)
Clone 12 BCL7 (healthy donor) A2/BMLF1; GLCTLVAML  
(Epstein–Barr virus)
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performed using fresh AnnexinV-binding buffer (14 mM NaCl, 
2.5 mM CaCl2, 10 mM Hepes) containing AnnexinV-FITC (BD 
Pharmingen). Where indicated, cells were stained with DAPI 
nucleic acid stain (Molecular Probes) at 150  ng/ml for FACS 
acquisition and 3 μg/ml for FACS sorting. Cells were acquired 
using the Gallios flow cytometer (Beckman Coulter, 3-laser con-
figuration) and data were analyzed using FlowJo (Tree Star Inc., 
v9.7.7). FACS sorting was performed with an Astrios cytometer 
(Beckman Coulter).
Chromium Release Assay
To evaluate the antigen-specific killing capacity of CTLs, a chro-
mium (51Cr) release assay was performed as described previously 
(17). In brief, melanoma cells were pulsed with 51Cr and cultured 
for 4  h at the indicated ratios with CD8+ T cell clones. Then, 
co-culture supernatant was transferred to LumaPlate™ 96-well 
plates (PerkinElmer) and its 51Cr content quantified with a Top 
Count NXT plate reader (PerkinElmer) as a measure of mela-
noma cell lysis.
RNA extraction
Cells were sorted directly into suspension media (PBS supple-
mented with 10% BSA and 0.05 M EDTA) and RNA was extracted 
using the Pico Pure™ RNA isolation kit (Arcturus) following the 
manufacturer’s Protocol B “RNA Extraction from Cell Pellets”. 
The optional freezing at −80°C directly after cell lysis and the 
optional on-column DNA digest were performed according to 
this protocol. The Qubit fluorometer (Life Technologies) was 
used to quantify the RNA and the 2100 Bioanalyzer (Agilent) 
served to determine the quality of the samples.
Microarray
A total of 1000 viable (DAPI negative) melanoma cells were 
sorted into SuperAmp lysis buffer (Miltenyi Biotec). RNA was 
isolated and gene expression was measured using an Agilent 
Whole Human Genome 8 × 60K (V2) microarray as described 
by Fuertes Marraco et  al. (19). The microarray data have been 
deposited in the NCBI Gene Expression Omnibus database with 
the accession number GEO: GSE79991.
Nanostring
RNA abundance was quantified with a custom-made set of probes 
by the iGE3 Genomics platform (University of Geneva) using the 
Prep Station and nCounter devices (NanoString Technologies) 
as previously described (20). The R software (version 3.2.2) and 
the NanoStringNorm package (version 1.1.19) were used for 
data analysis. First the average count of the negative controls 
was subtracted from the raw counts. Then the data were log2-
transformed. “NA” replaced undefined values (i.e. the ones result-
ing from log transformation of zero count values). Afterwards, a 
shift based on the normalization genes was defined using simple 
regression with the mean as offset. When log fold-changes were 
computed, a value of 10 was added to all normalized counts, the 
counts were averaged per condition, fold-changes were computed 
(treated/untreated) and eventually log2-transformed. We added 
10 to all counts before fold-change calculations to reduce the bias 
toward extremely high fold-change values when a gene had a very 
low expression level in the untreated condition.
ResULts
Characteristics of Melanoma Cell Lines 
and Cd8+ t Cell Clones
For our co-cultures, we selected low passage human melanoma 
cell lines that had been generated from melanoma metastases 
or tumor-infiltrated lymph node specimens (Table  1). The cell 
lines had been passaged for less than 6  months at the time of 
the experiments. To allow antigen-specific CTL–melanoma 
cell interactions with MelanA-specific CTL clones, we chose 
melanoma cell lines expressing MelanA and HLA Class I as 
determined by flow cytometry (Figure S1A in Supplementary 
Material). All melanoma cell lines were derived from HLA-A2 
positive patients (Table 1).
MelanA-specific CTLs had been previously cloned from 
patient blood (21). We selected CTLs specific for HLA-A2 and the 
MelanA26–35 decapeptide EAAGIGILTV that were capable of kill-
ing at least 50% of the tumor cells in a standard 4-h killing assay at 
a CTL:melanoma cell ratio of 10:1 (Table 2; Figures S1B and S2A 
in Supplementary Material). Killing assays with CTLs specific 
for non-melanoma antigens, such as epitopes from yellow fever 
virus (YFV) or Epstein–Barr virus (EBV), were used as negative 
controls to test if the observed CTL-induced reactions in tumor 
cells are dependent on antigen-specific interactions (Table  2). 
The killing was antigen-specific as MelanA-specific CTLs did 
not kill a MelanA-negative melanoma cell line (Figure  S2B in 
Supplementary Material) and negative control CTLs did not 
kill MelanA-expressing melanoma cell lines (Figure S2C in 
Supplementary Material). We estimated that such MelanA-
specific CTLs exert significant immune pressure and consequently 
provoke changes in the melanoma cells in co-cultures.
setup of Co-Culture
Melanoma cell lines are very heterogeneous in terms of growth 
speed, medium consumption (as determined by color of phenol-
containing medium) and time needed for the cells to adhere in 
tissue culture plates. For the co-culture, we seeded melanoma 
cells 2–3 days in advance, and then allowed interaction with CTLs 
for 3 days. Therefore, to establish comparable growth conditions, 
we determined for each cell line the seeding density at which 
cells would not be confluent before 6 days in any of the culture 
FIGURe 1 | timeline of co-culture experiments. In the case of intracellular FACS requiring addition of BrefeldinA, supernatant was taken before addition of 
BrefeldinA or from replicate cultures without BrefeldinA. Melanoma cell lines were thawed at least 1 week prior to the experiment.
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conditions. Depending on the cell line, between 35,000 and 
70,000 cells were seeded per 24-well in 2 ml. In addition, seeding 
densities were chosen based on only one medium change during 
the experiment (on the day that CTLs were added). This served 
to avoid removing any secreted factors that might participate in 
the co-culture.
To distinguish melanoma cells and CTLs by flow cytometry 
(FACS), melanoma cells were CFSE-labeled and CTLs violet 
tracker-labeled (Figure S3A in Supplementary Material). This was 
necessary, because during co-cultures, melanoma cells and CTLs 
change morphology, making it impossible to clearly separate the 
cell types based on forward and sideward scatter (Figure S3B in 
Supplementary Material).
The outline of the co-culture procedure was as follows: mela-
noma cell lines were seeded in advance (in general 3 days prior to 
the start of the co-culture) to allow them to adhere to the plastic 
(Figure 1), in 24-wells and 2 ml volume. On the day of co-culture 
start (day 0), 1 ml of medium was discarded and replaced with 
1 ml of fresh medium containing the respective treatment, i.e., 
CTL clones, cytokines (IFNγ, TNFα), or no treatment.
To maintain CTL viability, 30  U/ml of IL2 was added at 
treatment start, which was done for all cultures. Presence of IL2 
did not influence melanoma cells as we found similar protein 
expression with or without (data not shown). Depending on 
the condition of the melanoma cell lines, growth speed differed 
between experiments. Consequently, it was necessary to deter-
mine the melanoma cell number in two additional control wells 
on day 0 in order to calculate the number of CTLs required for 
the appropriate CTL:melanoma cell ratio (Figure 1).
Ratio and Viability of CtLs and  
Melanoma Cells in Co-Culture
To simulate co-existence of tumor-infiltrating CTLs and mela-
noma cells, we assessed the CTL:melanoma cell ratios where both 
cell types can persist for up to 3  days. Six CTL:melanoma cell 
ratios were tested (10:1, 1:1, 1:3, 1:10, 1:30, and 1:100) (data not 
shown). The three ratios showing co-existence during the co-
culture (3:1, 1:1, and 1:3) were chosen for further experiments. 
As expected, the melanoma cell:CTL ratio decreased during the 
3-day co-culture, indicating tumor cell killing by CTLs and/
or CTL proliferation (Figure  2; Figure S4 in Supplementary 
Material). MelanA-specific but not non-specific CTLs (YFV- or 
EBV-specific CTLs) killed the melanoma cell lines, demonstrat-
ing that the killing was antigen dependent. These observations 
are in accordance with the 4-h-killing assay shown in Figure S2 
in Supplementary Material.
To harvest the maximum number of viable cells, we tested 
different harvesting methods. Melanoma cells are adherent, 
whereas CTLs are not adherent. In addition, melanoma cells are 
fragilized in presence of MelanA-specific CTLs or their cytokines 
IFNγ and TNFα. Thus, quick and gentle harvesting was necessary. 
Collecting the supernatant, followed by one wash with PBS, a 
short incubation with accutase and harvesting the detached cells 
yielded the highest number of viable melanoma cells (Figure S5 in 
Supplementary Material). All liquids, including supernatant and 
washes, were collected.
To optimize viability of cells and achieve high-quality data, 
we minimized intervention on the cells after harvest. Particularly 
for RNA-based analyses rapid processing was crucial for RNA 
quality. To achieve lysis of sorted cells for RNA extraction within 
2  h from start of harvesting, no stainings were performed on 
harvested cells except from addition of DAPI for dead cell exclu-
sion. This was possible, because melanoma cell lines and CTLs 
had been labeled with CFSE and violet tracker prior to co-culture. 
Furthermore, samples were harvested sequentially to avoid wait-
ing times before sorting.
CtL Function in Co-Culture
Upon activation and antigen recognition, CTLs can not only kill 
target cells but also secrete the cytokines IFNγ and TNFα. To 
FIGURe 2 | CtL-mediated killing of melanoma cell lines in co-cultures is antigen-specific. Three different MelanA-specific CTL:melanoma cell ratios are 
shown in green. Yellow-fever-virus- or Epstein–Barr-virus-specific CTLs did not kill the melanoma cells (blue). The number of living cells was measured by flow 
cytometry. N = 2, except for T1185B 1:3 with MelanA-specific CTLs and 3:1 with neg. control CTLs N = 4. Error bars indicate SD.
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evaluate the functionality of antigen-specific CTLs, we quantified 
IFNγ and TNFα protein expression. Vesicle transport was blocked 
with BrefeldinA during 4 h before harvesting the co-cultures to 
allow intracellular FACS analysis. Indeed, antigen-specific but 
not control CTLs accumulated IFNγ and TNFα during the co-
culture (Figure 3). The cytokines accumulated primarily at 6 h. 
In the co-cultures with the lowest CTL-to-melanoma cell ratio 
(1:3), the percentages of cytokine-producing CTLs were highest. 
Furthermore, expression of IFNγ was more frequent than TNFα. 
Our observations are in accordance with the published literature 
indicating high cytokine production by CTLs when exposed to 
more tumor cells per CTL (22).
time-Point 48 h Is optimal for Protein 
expression Analysis
To test if the co-culture is a valid system to investigate CTL–
tumor cell interactions, we analyzed two markers whose 
behavior is known to change upon exposure to IFNγ or CTLs: 
HLA-DR and HLA Class I (23, 24). In addition, with the help 
of these markers we wanted to determine the best time-point 
to analyze melanoma cell responses to CTLs. As expected, 
although all cell lines expressed HLA Class I when untreated, 
its expression further increased in all cell lines upon co-culture 
(Figure 4). HLA-DR expression also increased in three out of 
four co-cultures. The three melanoma cell lines that showed an 
increase in HLA-DR expression had no or very low HLA-DR 
expression when left untreated whereas in the fourth cell line, 
T1015A, HLA-DR was constitutively expressed. Taken together, 
HLA Class I and HLA-DR behaved as expected with increased 
expression upon exposure to CTLs or their cytokines, support-
ing that the co-culture system is a valid approach to investigate 
tumor cell reactions to CTLs. For protein expression analysis, 
the 1:1 CTL:melanoma cell ratio at a 48-h time-point was the 
most appropriate setup, because strong protein expression 
changes were measured and, in addition, sufficient numbers of 
living melanoma cells could be harvested for reliable protein 
expression analysis.
time-Point 24 h Is suitable for mRNA 
screen of Co-Cultured Melanoma Cells
Currently, most screening methods for exploratory analyses of 
factors relevant to a biological process rely on mRNA samples. 
Screenings at the protein level, such as mass spectrometry-based 
proteomics, are still subjected to technical obstacles, such as lack 
of reproducibility (25), and require large amounts of cellular 
material. Thus, in order to explore changes at the genome-wide 
level and to allow for the detection of unexpected candidates, we 
wanted to test if the co-culture system is suitable for measurement 
of gene expression by microarrays.
First, we performed quantitative PCR (qPCR) experiments to 
test the feasibility of an mRNA-based screen and to assess whether 
changes known to happen at the protein level are also detectable 
at the mRNA level. We expected changes at RNA level to happen 
faster than at protein level. Based on the results obtained in the 
FIGURe 3 | Co-cultured antigen-specific CtLs produce cytokines. MelanA-specific CTLs accumulate intracellular IFNγ and TNFα with strongest expression at 
6 h of co-culture with the melanoma cell lines Me275 (top row) and Me290 (bottom row). Non-specific CTLs did not accumulate intracellular cytokines. Cytokine 
expression was measured by flow cytometry after intracellular staining of the co-cultured cells. N = 2, error bars indicate SD.
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previous section, the 1:1 (CTL:melanoma cell) ratio and the 24-h 
time-point were chosen for mRNA analysis to obtain sufficient 
numbers of surviving tumor cells. Indeed, in a preliminary 
experiment, the T1185B melanoma cell line yielded sufficient 
mRNA after co-culture or cytokine treatment to perform qPCR 
experiments. In accordance with the protein expression, HLA 
Class I mRNA was upregulated in the melanoma cell line after 
treatment with MelanA-specific CTLs or cytokines but not after 
treatment with non-specific CTLs (data not shown). MelanA 
mRNA decreased under these conditions in line with the obser-
vation that MelanA protein was downregulated after treatment 
with MelanA-specific CTLs or cytokines but not non-specific 
CTLs (Figure S6 in Supplementary Material) and in agreement 
with the literature (26). Our observations show that the changes 
at protein level can also be detected at the mRNA level with the 
1:1 ratio and the 24-h time-point.
Next, the microarray-based screen was performed on four 
melanoma cell lines, comparing 24-h treatment with MelanA-
specific CTLs versus untreated. Following culture, 1000 
melanoma cells were isolated from the co-culture by FACS 
(Figure  S7 in Supplementary Material) and relative RNA expres-
sion was measured using a gene expression microarray [Agilent 
Whole Human Genome 8 ×  60K (V2)]. The co-culture of the 
fourth cell line, T1015A, had to be omitted from the analysis 
due to insufficient sample quality (Figure S8 in Supplementary 
Material), illustrating that isolation of cells with sufficiently 
high mRNA quality from the co-culture is a technical challenge. 
From analysis of the three qualified co-cultures, 212 genes were 
at least fourfold differentially expressed between co-cultured 
and untreated samples across all three melanoma cell lines (184 
genes increased and 28 decreased; Figure 5A). Thus, our results 
show that mRNA screening of the co-culture system is techni-
cally feasible.
We wanted to confirm the reproducibility of the microarray 
results using a second frequently used mRNA-based technology. 
We chose the NanoString technology because it is highly quan-
titative and sensitive allowing the detection of several hundred 
individual mRNAs with a high dynamic range in a single reaction 
containing as little as 100 ng RNA. Furthermore, the technology 
is based on hybridization and does not require additional ampli-
fication or enzymatic steps making it less susceptible to unwanted 
bias (27). Finally, it allows studying more experimental condi-
tions at a more advantageous cost, as compared to microarray 
techniques.
Identification of Appropriate Normalization 
Genes for Nanostring Analyses: ALG12, 
GUSB, RPLP0, KRBA2 and ADAT2 Are 
stably expressed Genes and Not 
Influenced by CtLs or their Cytokines
For differential gene expression analysis by NanoString, a set 
of stably expressed genes is required to normalize for potential 
differences in loaded RNA quantities between samples. This is 
necessary since “global” normalization methods, such as those 
typically used for, e.g. microarray and RNA-seq data, are not 
appropriate in situations where only relatively few, non-randomly 
chosen genes are studied. However, the expression of some of the 
frequently used housekeeping genes in the above-mentioned 
microarray, including GAPDH, B2M and HPRT1, showed a large 
variability in expression among our samples (Figure 5B). Indeed, 
B2M expression is regulated by IFNγ, a cytokine secreted by acti-
vated CTLs (28). GAPDH is involved in functional networks that 
might be deregulated in cancer cells and is not suitable for studies 
in cancer cell lines (29). HPRT1 was expressed less stably than other 
housekeeping genes in a publication evaluating housekeeping 
FIGURe 4 | Melanoma cells increase hLA Class I and hLA-dR expression upon exposure to CtLs. Exposure of different melanoma cell lines to MelanA-
specific CTLs (green) or CTL-derived cytokines (black) but not to non-specific CTLs (blue) provoked changes of protein expression on the melanoma cells. Untreated 
cells are shown in red. HLA Class I was calculated as fold-change compared to untreated cells. HLA-DR is presented as % positive of living cells. Measurements 
were performed by flow cytometry. N = 2, error bars indicate SD.
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genes for the study of heart disease (30). The authors found HPRT 
expression to be influenced by age and hypoxia. Consequently, it 
is critical for the interpretation of gene expression data to confirm 
the stable gene expression of frequently used normalization genes 
under co-culture conditions and to identify additional suitable 
normalization genes if necessary.
FIGURe 5 | Gene expression of co-cultured compared to untreated melanoma cell lines. (A) Distribution of all log fold-changes between the treated and 
untreated condition for each of the cell lines. N = 41,839 probes, bandwidth = 0.06145. (b–d) Expression of “housekeeping” genes in microarray data set. (b) 
Frequently used normalization genes. (C) Stably expressed genes with <0.25 SD across all samples and stable expression according to the Genevestigator tool. (d) 
Control genes suggested by the RefGenes tool in Genevestigator.
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To find a collection of stably expressed genes that can be used 
to normalize gene expression from the very high to very low 
expression range, we first extracted all genes with a SD below 
0.25 in the microarray experiment and the average expression 
level for these genes (average expression across all samples and 
cell lines). From this list, we evaluated some of the genes with 
Genevestigator,1 to see the variability of their expression across a 
large number of microarray experiments. From this evaluation, 
1 www.genevestigator.com
the most promising candidates are visualized in Figure  5C. 
Among these genes, at least BECN1, SEC24C, and DIRC1 also 
showed stable expression based on GeneProf,2 which is based 
on RNA-seq data. We did a search for stable genes using the 
RefGenes tool in Genevestigator, and found new candidates, but 
again only a fraction of these candidates were stably expressed in 
the microarray (Figure 5D). Based on these analyses, we chose 
eight genes for normalization of future mRNA analysis with the 
2 www.geneprof.org
FIGURe 6 | stably expressed genes detected by microarray and Nanostring. (A) 185 genes with different expression levels were chosen for quantification by 
NanoString. Shown is the average expression measured by microarray from all samples on the x-axis and the average log fold-change between the co-cultured and 
the non-co-cultured samples across the three melanoma cell lines (Me290, Me275, and T1185B) on the y-axis. For the planned NanoString, the normalization genes 
(blue) were chosen to span a wide range of expression values but without changes between the treated and untreated cell lines. Red dots, genes selected for 
NanoString; blue dots, normalization genes for NanoString; gray dots, genes that were only measured by microarray. (b) Normalized gene expression values of all 
samples analyzed by NanoString. Red lines indicate expression levels of genes used for normalization (order from highest to lowest expression: RPLP0, GUSB, 
ALG12, ADAT2 and KRBA2). Treatment color code: Black, MelanA-specific clone 1; green, cytokines; cyan, negative control CTLs; blue, untreated; red,  
MelanA-specific Clone 121. Samples are shown in the same order as they were run on the NanoString cartridge.
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NanoString platform (ADAT2, ALG12, DIRC1, GUSB, KRBA2, 
PHKG1, RPLP0, and SLC26A3).
We then assembled a set of 185 genes covering all expression 
levels and degrees of differential gene expression in the microar-
ray to study their expression by NanoString (Figure 6A). For this 
experiment, we pooled the cells of several 24-wells containing 
the same treatment condition in order to collect higher numbers 
of living melanoma cells (between 3 and 12 wells depending on 
the culture condition and the number of viable cells expected 
with a given treatment). Out of the eight chosen control genes, 
three were not used for normalization because they showed a 
very low level of expression (DIRC1, SLC26A3, and PHKG1). The 
FIGURe 7 | Comparison of microarray and Nanostring data for 
samples and genes that were measured in both experiments. Shown 
is the log2 fold-change (co-cultured/untreated) of the three melanoma cell 
lines (A) Me275, (b) Me290 and (C) T1185B.
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remaining control genes (ALG12, GUSB, RPLP0, KRBA2, and 
ADAT2) that showed sufficiently high gene expression were used 
for normalization (Figure 6B).
In addition to the purity check upon cell sorting, potential 
CTL contamination in melanoma cell samples isolated from the 
co-cultures was checked by including a series of CTL markers on 
the NanoString (CD3D, CD3E, CD3G, CD8A and CD8B). In all 
samples, the normalized expression values of all CTL markers 
were below the threshold for background, except for CD3D, for 
which two culture conditions (Me275 and T1185B with MelanA-
specific Clone 1) were slightly above the threshold but still very 
low. Since the CD3 and CD8 levels were also slightly increased 
in the cytokine-treated samples (i.e. in absence of CTLs), we 
assume that the potential CTL contamination was negligible, that 
the probe showed cross reactivity or that these genes might be 
expressed at low background levels by the melanoma cell lines 
(Figure S9 in Supplementary Material).
Finally, we compared the results of the microarray and of 
the NanoString experiments. The differential gene expression 
in the microarray correlated well with the NanoString, but the 
microarray generally underestimated the log fold-change com-
pared to the NanoString (Figure 7). The reason for this may be 
that the background intensities on the microarray may lead to 
more heavily biased fold-changes compared to the NanoString. 
It has previously been observed that microarray analysis show 
global compression that is most extreme for very high and low 
gene expression values (31). In addition, for the NanoString, 
more cells were sorted (30,000–300,000 cells per sample for 
the NanoString experiment versus 1000 cells per sample in 
the microarray experiment) and no global amplification of the 
isolated mRNA was necessary. Together, our data show that 
sufficient and high-quality mRNA can be isolated from the 
co-culture system to perform genome-wide differential gene 
expression analysis and that the experimental system yields 
reproducible results.
dIsCUssIoN
It is becoming increasingly clear that CTLs can not only kill 
cancer cells but also provoke changes of the tumor microenviron-
ment with consequences that may impact on the patient’s clinical 
outcome. Here, we describe the setup of an in  vitro co-culture 
system of human melanoma cell lines and melanoma-specific 
CTLs, including quality control and fine-tuning of experimental 
parameters. Previously published approaches describe mouse 
models and long-term culture escape variants of tumors and cell 
lines (4, 6–8, 32). By contrast, our two-component in vitro system 
allows to study the CTL–tumor cell interactions in human mate-
rial and the analysis of much more rapidly occuring reactions 
in a widespread and detailed manner using well-defined and 
reproducible culture conditions.
The tumor microenvironment is infiltrated with different types 
of immune and other host cells. In this heterogeneous tissue, it is 
difficult to study cause–effect relationships of specific cell types. 
The two-component-culture system described here is suitable to 
study the CTL–melanoma cell relationship because no other cell 
type or stroma component is confounding the interaction. This 
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is a reductionist model that excludes  interactions with other cell 
types of the tumor microenvironment, thus conversely, the model 
alone does not allow direct conclusions on in vivo functions.
With this co-culture setup, we could successfully isolate suf-
ficient numbers of viable cells for protein and mRNA analyses 
with high-quality data, including genome-wide screens and 
broad quantitative gene expression analysis. Importantly, our 
mRNA-based microarray and NanoString screens revealed that 
frequently used normalization genes are not stably expressed 
in melanoma cells exposed to melanoma-specific CTLs or their 
cytokines (IFNγ/TNFα). In turn, we identify ALG12, GUSB, 
RPLP0, KRBA2 and ADAT2 to be suitable normalization genes for 
expression analysis in our co-culture system. Beyond the culture 
system described here, these normalization genes could find wide 
use in studies of immune-related culture and expression systems 
and even in direct ex vivo analysis of human surgery specimens in 
which CTLs or other cytokine-secreting cells are present.
In addition to studying direct gene expression changes of 
melanoma cells upon exposure to CTLs, this co-culture system 
can be employed for a series of yet unanswered questions. As 
an example, assessing the reversibility of rapid reactions in 
the co-cultured melanoma cell lines may be important for the 
understanding of CTL–melanoma cell dynamics. In a study by 
Landsberg et al. melanoma-bearing mice relapsed after adop-
tive T cell therapy. Interestingly, the relapsing tumors showed 
inflammation-induced reversible changes of melanocytic anti-
gen expression. The authors proposed a dynamic equilibrium 
between differentiated and dedifferentiated tumor cells (8). Our 
culture system is suitable to address whether this equilibrium 
or other CTL-induced changes can also be observed in  vitro. 
To study reversibility, we re-cultured melanoma cells that were 
isolated from a 24-h co-culture with CTLs. One out of four 
tumor cell lines grew back to sufficient density for analysis, 
demonstrating the potential of our co-culture system to answer 
this question. In this preliminary analysis, we found that the 
expression of the target antigen MelanA was lost in half of the 
living tumor cells, but returned to normal levels in cultures 
(without CTLs) after further 6 and 16  days, suggesting that 
decreased expression of MelanA is reversible. This finding is 
in line with a previously published study of T cell therapy in 
a mouse melanoma model (8). Similarly, the inhibitory recep-
tor ligand PDL1 is upregulated at RNA and protein level in 
MelanA-specific co-cultures, but decreased to baseline levels 6 
and 16  days after melanoma cells were isolated from the co-
culture. However, more experiments are necessary for definitive 
conclusions.
Another example is based on the observation that the peptide 
repertoire on the surface of tumor cells can be shaped by CTLs. 
It has been reported that CTLs with low affinity for their target 
antigen may strip target-peptide-loaded major histocompatibility 
complexes (pMHC) from the surface of tumor cells without lysing 
them (33). Subsequently, the lower abundance of target antigen 
on the tumor cell surface may be insufficient for lysis, even by 
high-affinity CTLs. However, this study did not analyze whether 
additional changes occurred in the tumor cells. In our co-culture 
system, the melanoma-specific CTLs have been chosen based 
on their ability to lyse melanoma cells. It would be interesting 
to investigate the effects of melanoma-specific low-affinity CTLs 
that lack the ability to lyse their target cell in our experimental 
system.
CoNCLUsIoN
Our short-term co-culture system is well suited to characterize 
the early and dynamic interplay of melanoma cells and CTLs 
because the setup allowed the isolation of sufficient viable cancer 
cells for high-quality protein and mRNA expression data. We 
furthermore, identified appropriate genes for normalization of 
gene expression data that are not the commonly used as standard 
normalization genes. Our system has the potential to address 
questions relevant for T cell-based immunotherapies that are 
directly related to the effects of CTL attack on cancer cells.
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